Skip to main content
OKUR logo

OnKure Therapeutics, Inc. (OKUR) Stock: Price, Forecast & Analyst Target

OnKure Therapeutics, Inc. (OKUR) — MoonshotScore 57/100 (Fair band), calculated Nov 18, 2026. Price $2.70 (-2.17%), as of the Nov 20, 2026 trading session; market cap $111M.

Educational signal · not a buy or sell recommendation · How to read this

$2.70 −$0.06 (-2.17%) Market Cap $111M

OnKure Therapeutics, Inc. · OKUR · NASDAQ

OnKure Therapeutics, Inc. is a biotechnology company focused on developing oncology-precision medicines.

Price as of Nov 20, 2026

Key Statistics

57 of 100

MoonshotScore v2 · OnKure Therapeutics (OKUR)

Fair
Business Quality Average (40)
Financial Safety Sound (64)
Valuation Fair (79)
Growth Durability Flat (50)
Momentum Quiet (44)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Middling on every pillar — nothing weak enough to single out, nothing strong enough to stand on. Business Quality: Average; Financial Safety: Sound; Valuation: Fair; Growth Durability: Flat; Momentum: Quiet.

  • EPS beat 5 of the last 8 reports
  • Altman Z 4.42 · Piotroski F 2
  • ROE -43.4% · ROA -37.0% · current ratio 18.84 · earnings yield -47.1% · free-cash-flow yield -45.0%

Helping: an attractive price

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for OKUR (58 recorded, newest six shown)
RecordedScoreBand
58Fair
56Fair
56Fair
57Fair
57Fair
57Fair

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$2.70
Change on the day-2.17%
Market capitalisation$111M—
Shares traded on the day195.2K

Price & events

Other perspectives

Council score for OnKure Therapeutics (OKUR): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Neutral
Financial Safety Moderate
Valuation Moderate
Growth Durability Neutral
Momentum Neutral

Legends Council

4 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Unfavorable read

Read on: Oct 9, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Weak
Margin of Safety Undervalued
Profit Margin Weak
Revenue Growth Weak
Debt/Equity Strong
ROE Negative
Gross Margin Negative

Read on: Oct 8, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Oct 8, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.

Readings on this page are from Nov 21, 2026, except a card that shows its own read date.

1 · What is it?

What is OnKure Therapeutics (OKUR), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. OnKure Therapeutics, Inc. (OKUR) is listed on NASDAQ. It employs 45 people. The market values it at $111M.

2 · Latest results

What do the latest results show for OnKure Therapeutics (OKUR)?

Short answer · as of

Against analyst estimates the company has EPS beat 5 of the last 8 reports.

3 · Financial strengths and risks

What are the financial strengths and risks for OnKure Therapeutics (OKUR)?

Short answer · as of

The MoonshotScore pillars rate an attractive price as strengths. The distress and quality screens read Altman Z 4.42 · Piotroski F 2. Trailing ratios: ROE -43.4% · ROA -37.0% · current ratio 18.84 · earnings yield -47.1% · free-cash-flow yield -45.0%.

Data-derived red flags

  • Negative return on equity (-43.4%) — the business is not currently generating profit on shareholder capital.
  • Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
4 · What to check next?

What should you watch next at OnKure Therapeutics (OKUR)?

Short answer · as of

Analyst estimates on file carry FY2026 revenue $250,000 · EPS -1.61 · 3 analysts. Current published price targets run low $14.00 · high $14.00 · consensus $14.00 · median $14.00 against a quoted price of $2.70 (as of Nov 20, 2026).

What the records here don't tell us

  • The next earnings date is not yet scheduled in the calendar we read.
  • No insider Form 4 transaction falls inside the window this page reads.
  • No quarterly income statement is held for OKUR.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does OnKure Therapeutics compare with its peers?

Short answer

OnKure Therapeutics's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Fennec Pharmaceuticals Inc. (FENC) Same industry, near in market value$13.45 Nov 19, 2026$475M91 5-pillar Nov 18, 2026
Zevra Therapeutics, Inc. (ZVRA) Same industry, near in market value$8.76 Nov 20, 2026$521M91 5-pillar Nov 18, 2026
Protalix BioTherapeutics, Inc. (PLX) Same industry, near in market value$2.90 Nov 20, 2026$245M90 5-pillar Nov 18, 2026
Rigel Pharmaceuticals, Inc. (RIGL) Same industry, near in market value$40.09 Nov 20, 2026$755M88 5-pillar Nov 18, 2026
ImmuCell Corporation (ICCC) Same industry, near in market value$10.92 Nov 20, 2026$99.3M82 5-pillar Nov 18, 2026
Rallybio Corporation (RLYB) Same industry, near in market value$15.47 Nov 20, 2026$86.6M82 5-pillar Nov 18, 2026
Gilead Sciences, Inc. (GILD) Named competitor$166.53 Nov 19, 2026$207B72 5-pillar Nov 18, 2026
Oramed Pharmaceuticals Inc. (ORMP) Same industry, near in market value$3.69 Nov 19, 2026$160M72 5-pillar Nov 18, 2026
Compugen Ltd. (CGEN) Same industry, near in market value$1.84 Nov 20, 2026$174M69 5-pillar Nov 18, 2026
Climb Bio, Inc. (CLYM) Same industry, near in market value$9.19 Nov 20, 2026$540M68 5-pillar Nov 18, 2026
MeiraGTx Holdings plc (MGTX) Same industry, near in market value$7.98 Nov 20, 2026$780M63 5-pillar Nov 18, 2026
Alopexx, Inc. (ALPX) Same industry, near in market value$10.02 Nov 20, 2026$148M61 5-pillar Nov 18, 2026
OnKure Therapeutics (OKUR) — this page$2.70$111M57

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$14.00 – $14.00
Consensus target
$14.00
Median target
$14.00
Revenue estimate
$250,000
EPS estimate
$-1.61

Consensus record · Captured .

Measured against a quoted price of $2.70 (as of Nov 20, 2026).

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held OKUR in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported OKUR in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

OnKure Therapeutics Stock: Key Questions Answered

These answers are editorial: they are written from question templates that restate figures shown above. They are not part of the source register.

What does the MoonshotScore mean for OKUR?

OKUR carries the MoonshotScore stated above — the Fair band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.

Is OKUR a good stock to buy?

Stock Expert AI does not rate OKUR buy, sell or hold. OnKure Therapeutics, Inc. carries a MoonshotScore, in the Fair band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the OKUR stock price today?

The last price recorded for OnKure Therapeutics, Inc. (OKUR), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the OKUR price target?

The analyst consensus price target for OnKure Therapeutics, Inc. (OKUR), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

What are the key factors to evaluate for OKUR?

OnKure Therapeutics, Inc. (OKUR) holds a MoonshotScore in the moderate range. To weigh it, read the analyst view under Analyst targets & estimates on this page. OnKure Therapeutics focuses on oncology-precision medicines, indicating a targeted approach to cancer treatment. Not financial advice.

How frequently does OKUR data refresh on this page?

OKUR's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven OKUR's recent stock price performance?

OnKure Therapeutics, Inc. (OKUR) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focused on oncology-precision medicines. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider OKUR overvalued or undervalued right now?

OnKure Therapeutics, Inc. (OKUR) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Can I buy fractional shares of OKUR?

Fractional-share availability for OnKure Therapeutics, Inc. (OKUR) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 17 figures on this page — 9 from Financial Modeling Prep (FMP), 7 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.